Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore.

De Keersmaecker K, Rocnik JL, Bernad R, Lee BH, Leeman D, Gielen O, Verachtert H, Folens C, Munck S, Marynen P, Fornerod M, Gilliland DG, Cools J.

Mol Cell. 2008 Jul 11;31(1):134-42. doi: 10.1016/j.molcel.2008.05.005.


In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.

De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, Vandenberghe P, Odero MD, Marynen P, Cools J.

Haematologica. 2008 Apr;93(4):533-42. doi: 10.3324/haematol.11894. Epub 2008 Mar 5.


A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome.

La Starza R, Rosati R, Roti G, Gorello P, Bardi A, Crescenzi B, Pierini V, Calabrese O, Baens M, Folens C, Cools J, Marynen P, Martelli MF, Mecucci C, Cuneo A.

Leukemia. 2007 Apr;21(4):830-3. Epub 2007 Feb 15. No abstract available.


Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent.

Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, Williams IR, Gilliland DG, Cools J.

Proc Natl Acad Sci U S A. 2006 May 23;103(21):8078-83. Epub 2006 May 11.


Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W, Boogaerts M, Vandenberghe P, Marynen P, Cools J.

Blood. 2006 Aug 15;108(4):1374-6. Epub 2006 Apr 27.


Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M.

Clin Cancer Res. 2006 Apr 15;12(8):2622-7.

Supplemental Content

Loading ...
Support Center